This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Prof Tom Powles and Prof Robert Jones share their thoughts on the KEYNOTE-045 clinical trial results

Prescribing Information

KEYTRUDA® (pembrolizumab):

Prescribing Information

Length: 04:17

Prof Tom Powles and Prof Rob Jones discuss their thoughts on KEYNOTE-045 phase 3 trial of pembrolizumab vs chemotherapy (paclitaxel, docetaxel or vinflunine) in patients with locally advanced or metastatic urothelial cancer.

More information about KEYTRUDA:

Supporting documentation

GB-PDO-01012 | Date of Preparation: June 2020